How The UK, EU, Canada, Australia And Japan Are Tackling Diversity In Clinical Trials

As efforts to improve diversity in clinical trials gain momentum globally, the Pink Sheet asked regulators in the UK, the EU, Canada, Australia and Japan about their efforts to support representative enrolment. 

Diversity And Inclusion At Workplace. Inclusive Hiring And Insurance
Clinical trial participants should represent the population that will be using the drug • Source: Shutterstock

The need to improve diversity among clinical trial participants has been recognized for some time now, but the issue gained prominence during the COVID-19 pandemic when discussions around inequitable access to research and treatments became more pronounced.

While all eyes are on the US where new legislation has mandated sponsors of Phase III and pivotal trials to develop diversity action plans detailing the rationale and targets for enrolling participants based on age, ethnicity, sex and race, other countries are also taking steps to address the issue

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regional Comparisons

More from Pink Sheet

Global Pharma Guidance Tracker - April 2025

 

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk

 
• By 

Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.